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This paper examines the processes by which new drug
candidates are discovered, especially the early stages of
this discovery process. Excluding compounds that are
licensed-in, three distinct sources of lead compounds are
generally recognized:
Medicinal chemistry.
Empirical screening.
Rational drug design.
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The salient features of each approach are first discussed.
The evolution of a set of regulatory and business
conditions that seemed to favour one of these approaches
to the detriment of the others are next examined; finally,
the way in which recent developments in automation may
have served to establish a new equilibrium between these
three lead discovery systems is described.
Medicinal chemistry
Medicinal chemistry is the first of the modern drug
discovery methods. It has given us many ofthe medicines
available today. At its best medicinal chemistry combines
a comprehensive knowledge of the medicinal chemistry,
synthetic chemistry and pharmacology literature with the
ability to imagine what no one else has imagined and then
the drive to reduce the concept to synthetic practice. The
best of the medicinal chemists also have the ability to
think somewhere beyond three dimensions and are able
to stretch analogous reasoning way beyond normal limits.
A good example of medicinal chemistry is the program
that led from Asperlicin (figure 1), a weak, fermentation-
derived cholecystokinin antagonist to an orally active
compound (figure 2) 16000 times as potent [1]. The
major limitation of medicinal chemistry is that what one
starts with is already a known compound. It is therefore
inherently less innovative than either of the other two
methods discussed in this paper.
Empirical screening
Empirical screening is also called non-selective, random,
blind, mass and broad screening. The object ofevery real
screener, whether he or she is conscious of it or not, is to
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Figure 2. Synthetic chemistry based on original structure.
screen ’all of creation’. ’Numbers’ is the name of the
game. No one ever accused screeners of being choosey.
The unique advantage of this approach is that many of
the active compounds discovered are of totally unex-
pected structures. Good examples are the previously
mentioned Asperlicin and the anti-hypercholesterolemic
twins, Mevinolin and Pravastatin (see figures 3 and 4).
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Automation and Robotics (October 1992, Boston, USA). Figure 3. Mevinolin.
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Figure 4. Pravastatin.
Rational drug design
This approach is based on the very reasonable assump-
tion that ifone knew the structure ofa natural ligand and
of its receptor, one should be able to say something useful
about the kind of molecules that might mimic or
antagonize the activity of the natural ligand. In this
approach much reliance is placed on:
(1) X-ray crystallography.
(2) Very high-field NMR.
(3) Computer assisted molecular modelling.
(4) Quantum mechanical calculations.
(5) Cloning and expression of receptors.
(6) Peptidic ligands.
Not all of this is the ’new approach’ that many people
think it is. By the mid 1960s, Max Marsh at Eli Lilly had
already set up a quantum chemistry group that success-
fully applied quantum mechanical calculations to a real
medicinal chemistry SAR. The fact that they needed the
corporate mainframe for weekend after weekend to do the
analysis on just a few compounds may be one reason this
effort never had a sustained impact on the Lilly research
programmes. Although today’s computers are much
more powerful than those of 1965, the time required to
carry out a complex calculation is still inordinately long.
To model 100 picoseconds of the dynamics of the HIV-1
protease dimer (a total of 198 amino-acid residues),
required 90 hours on the Cray computer at Wesleyan
University [2].
Rational Drug Design (RDD) programmes have not, as
yet, many successes to point to but interesting and
potentially useful application have been described for
inhibitors of Renin [3], HIV-1 Protease [4] and the
Carbonic Anhydrase associated with glaucoma [5].
Several factors have contributed to ’Rational’ approach
growing from virtually nothing in 1980 to its current
significant size"
(1) Rapidly increasing costs.
(2) Longer development times.
(3) The ’mega-drug’ phenomenon.
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Figure 5. R&D Expendituresfor PMA memberfirms.
Complicating the situation is what I see as an ironic result
of a public relations campaign undertaken by our
industry. The ethical pharmaceutical industry has had a
long-standing campaign to inform the public of the
difficulties inherent in discovering and developing a new
drug. This campaign, run by the Pharmaceutical Manu-
facturer’s Association (PMA), has placed great emphasis
on the low odds offinding a usable compound. Typically
the odds are given as 1:10 000, although an Eli Lilly VP
(Mitchell Daniels) suggested recently (Scrip, April 1992)
that the real odds are closer to 1:50 000. The public is
then told that: ’we have to synthesize/screen 10000 or
even 50 000 compounds in order to discover one drug and
then we have to spend 8 years and $200 000 000 to bring it
to market’.
Probably the actual nunbers are, to some extent,
unimportant, but I believe that some, at least, in our
industry came to accept the PMA mantra as fact. Faced
as they were with rapidly escalatin costs, the prospect of
a new approach that might reduce costs and shorten
development times was very seductive.
Rational Drug Design has been the object of enormous
hype. A particularly florid example is the following from a
Forbes article of 2 April 1991 by Julie Pitta.
’By the end of the decade such "rational drug design"
may account for half the research dollars spent at large
pharmaceutical houses... Apart from producing drugs
with fewer unwanted side effects.’
Or the prediction from a corporate VP (Brian Metcalf,
SKB, quoted in Scientific American, January 1990)"
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Figure 7. Earnings performance of 100 drugs versus R&D cost.
’We see "rational drug design’ as the key to the future. We
are close to exhausting the traditional approaches.’
No major pharmaceutical company, that I know of,
reveals how much of its R&D budget is devoted to the
rational approach, although there are several small
companies that are so completely dedicated to this
approach that one can assign essentially all their research
budgets to RDD [6].
In order to get some idea of the magnitude of the
investment being made by the major American pharma-
ceutical companies, I have used information supplied by
colleagues at a number of pharmaceutical companies.
This was then supplemented by trade information from
the CADD hardware and software industry whose sales
are significantly affected by the rate of spending by
pharmaceutical companies on RDD.
This admittedly hit-and-rniss approach yields numbers in
the range 5 to 10% of the drug discovery budget being
spent on RDD approaches in 1991. With a number of
R&D budgets slated to reach or exceed the $1 billion
mark in 1993 and assuming 20-25% being spent on ’R’,
one can calculate that $10 to $25 M a year is being spent
on Rational Approaches for every $1 billion in R&D
expenditure. The member firms of the PMA will spend
$10 billion on R&D in 1993. This translates into
something in excess of $100 M for Rational Drug Design
programmes.
Between 1980 and 1990, the US pharmaceutical industry
R&D budget grew at an average annual rate of 15%.
From 1984 to 1990, rational drug design budgets appear
to have grown at over 20% a year. There are indications,
however, that this rate has slowed in the past two years.
Few believe that Pitta’s prediction ofonly last year willbe
fulfilled. So, what, if anything, has happened?
Apart from the relative lack of measurable success from
the RDD approach, a failure that has been unfortunately
magnified by the hype ! referred to earlier, something else
was happening during the 1980s. Some of us in the
industry believe that its impact will be at least as
significant as that of RDD. I am referring, of course, to
laboratory automation with particular emphasis on
material handling equipment.
When I departed Eli Lilly in 1982 they were still running
their fermentation screens in agar. At that time both Lilly
and Bristol-Myers (Tokyo) wei’e running 100 to 200
fermentations a week, i.e. 5000 to 10000 fermentation
samples a year in, perhaps, 10 assays (screens) and a
clear distinction was made between fermentation samples
and synthetic compounds from the corporate files.
Between 1980 and 1990 the whole world of screening
changed as reflected by William Netzer in an article in the
July 1990 Biotechnology, in which he describes Merck as
’perhaps the. most prolific screener’ claiming that they are
now screening’ as many as 40 000 satnples a year in as
many as 60 screens’. But Merck is by no means alone in
this. Eli Lilly now has a well-equipped system distribut-
ing samples, both natural and synthetic, for screening.
Similar systems already exist, or are being developed, in
most major pharmaceutical companies, including Bris-
tol-Myers Squibb. Overall, the sample throughput capa-
bility appears to have increased 5 to 50 fold since the ’old
days’ of a decade ago. During the same period the
manpower required for the running ofa typical screen has
probably decreased slightly. The question for us here
today is ’how did this come about?’
There were a number of important contributors to this
amazing increase in productivity. The single most
important ttctor, in my opinion, was the development
and widespread use of the 96-well microplate. In terms of
importance this is closely followed by the introduction of
multi-channel pipettes, followed by the first of the
programmable pipetters, the serial diluters, the micro-
plate readers, mini-barcode printers and readers, pro-
grammable material handling systems and the use of
robots in a fetch-and-carry mode to permit overnight
operation.
The result of all of this is that even if the gloomy statistics
of in 50000 were correct, by using a combination of
fermentation broth-derived samples and synthetic com-
pounds from corporate archives or other sources, one
should be able to find one to two new leads every year in
every screen.
At the beginning ofthis paper, the establishment ofa new
equilibrium between the three major lead discovery
approaches was mentioned. In several companies, this
seems to have already occurred, due largely to the
revolution in screening automation and the steady stream
of novel leads that have emerged from the screening
programmes.
A good example ofthis is a recent target that was attacked
simultaneously by each of the three approaches.
Endothelin, the most potent endogenous pressor agent
(blood-pressure raising compound) was first reported by
Yanagisawa in 1988. It is a 21-AA peptide whose
sequence and synthesis were also reported that same
year. Many medicinal chemistry groups immediately
started peptide synthesis programmes to delineate theS. O’Connor The drug discovery process
requirements for binding to the receptor and for func-
tional activity. The results ofthis approach have not been
particularly useful or revealing since, almost by defini-
tion, peptides do not have many of the properties desired
in a drug.
Meanwhile, the rational designers set out to clone one or
more of the ET receptors. This was not accomplished
until 1992. The receptor has still not been crystallized
and, therefore, no X-ray structure data is yet available.
While all this was going on, Merck-Banyu, Fujisawa,
Bristol-Myers Squibb and an unknown number of other
companies were screening everything in sight for com-
pounds that would specifically inhibit the binding of
endothelin to its receptor.
In May 1991 a note from Banyu (Merck) in Tokyo
reported the isolation and characterization of a fermen-
tation-derived antagonist [7]: It is a cyclic pentapeptide
whose structure quickly became the focus of a successful
medicinal chemistry programme. A rough guess would be
that Banyu discovered their antagonist in January 1990.
Banyu’s report was followed by one from Fujisawa [8].
They had found the same cyclic peptides and subse-
quently found a non-peptide antagonist [9]. I expect by
now everyone has some kind of a lead from either
fermentation or synthetic screening or, as at Bristol-
Myers Squibb, from both.
The extraordinary sample handling and screening capa-
cities that are now integral to the research programmes of
a number of the major pharmaceutical companies have
changed the world oflead discovery. We now know with a
fair degree ofcertainty that, given a year, we can supply a
novel lead for almost any target or research programme.
We cannot guarantee that the lead will necesssarily be
useful but, then, no one else can make that promise either.
The mere possession of such a lead provides a starting
point for a medicinal chemistry programme. Rational
drug design also benefits from the discovery of these
leads, although somewhat less directly. True synergy
between the different approaches has been restored and
we are all enriched by it.
Today’s problems are no longer concerned with through-
put, instead we now find ourselves running out of
materials to screen. Fortunately, soil micro-organisms are
probably generating new strains faster than we can screen
them and, given the need for fresh sources of screening
samples, what better time than now for the rain forests to
come into their own as unique sources of secondary
metabolites?
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